Display options
Cite
Seeber A, Gastl G, Ensinger C, et al. Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes Cancer. 2016;7(9):301-308doi: 10.18632/genesandcancer.121.
Seeber, A., Gastl, G., Ensinger, C., Spizzo, G., Willenbacher, W., Kocher, F., Leitner, C., Willenbacher, E., Amann, A., Steiner, N., Eisterer, W., Voss, A., Russell, K., & Zwierzina, H. (2016). Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes & cancer, 7(9), 301-308. https://doi.org/10.18632/genesandcancer.121
Seeber, Andreas, et al. "Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project." Genes & cancer vol. 7,9 (2016): 301-308. doi: https://doi.org/10.18632/genesandcancer.121
Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H. Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project. Genes Cancer. 2016 Sep;7(9):301-308. doi: 10.18632/genesandcancer.121. PMID: 28050231; PMCID: PMC5115171.
Copy Download .nbib Format: NLM
Share it on

Genes Cancer. 2016 Sep;7(9):301-308. doi: 10.18632/genesandcancer.121.

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Genes & cancer

Andreas Seeber, Guenther Gastl, Christian Ensinger, Gilbert Spizzo, Wolfgang Willenbacher, Florian Kocher, Christoph Leitner, Ella Willenbacher, Arno Amann, Normann Steiner, Wolfgang Eisterer, Andreas Voss, Kenneth Russell, Heinz Zwierzina

Affiliations

  1. Department of Haematoloy and Oncology, Innsbruck Medical University, Austria; Laboratory for Experimental Oncogenomics, Tyrolean Cancer Research Institute, Austria.
  2. Department of Haematoloy and Oncology, Innsbruck Medical University, Austria.
  3. Department of Pathology, Innsbruck Medical University, Austria.
  4. Haematooncological Day Hospital, Hospital of Merano, Italy.
  5. Caris Life Sciences, Basel, Switzerland.

PMID: 28050231 PMCID: PMC5115171 DOI: 10.18632/genesandcancer.121

Abstract

INTRODUCTION: Patients with refractory metastatic cancer have been shown to benefit from molecular profiling of tumor tissue. The ONCO-T-PROFILE project was launched in March 2014 at the Innsbruck Medical University. Within 2 years our project aims to recruit 110 patients with stage IV cancer refractory to standard therapy. Our data presented here are based on an interim-analysis.

METHODS: Tumor tissue specimens were submitted for molecular profiling to the certified laboratory (Caris Life Science, USA). Druggable tumor targets were selected based on biomarker status to agents with potential clinical benefit. Clinical benefit was defined as a PFS ratio (=PFS upon treatment according to the molecular profile/ PFS upon the last prior therapy) ≥ 1.3.

RESULTS: As of April 2015, tumors from 50 patients have been molecularly profiled and one or more targets were detectable in 48 specimens (98%). So far, 19 (38%) patients have been treated according to their molecular tumor profile. To date, 8 (42%) patients have reached a PFS ratio of ≥ 1.3.

CONCLUSIONS: We could show that molecular profiling is feasible in the clinical routine. A proportion of patients might benefit from an individualized treatment approach based on molecular profiling. As a result, we will proceed to enroll patients in ONCO-T-PROFILE.

Keywords: cancer; caris life sciences; molecular profiling; next generation sequencing; personalized medicine

Conflict of interest statement

AS, GG, HZ served as consultant and were in the advisory board of Caris Life Sciences.

References

  1. Nat Med. 2011 Mar;17(3):304-12 - PubMed
  2. N Engl J Med. 2010 Jun 24;362(25):2380-8 - PubMed
  3. J Clin Oncol. 2001 May 15;19(10):2722-30 - PubMed
  4. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  5. J Clin Oncol. 2010 Nov 20;28(33):4877-83 - PubMed
  6. Lancet Oncol. 2015 Oct;16(13):1324-34 - PubMed
  7. Clin Genitourin Cancer. 2015 Feb;13(1):e37-49 - PubMed
  8. Curr Oncol. 2014 Feb;21(1):e151-4 - PubMed
  9. Breast Cancer Res Treat. 2014 Oct;147(3):579-88 - PubMed
  10. Nature. 2012 Oct 4;490(7418):61-70 - PubMed
  11. J Clin Oncol. 2015 Dec 1;33(34):4023-31 - PubMed
  12. N Engl J Med. 2015 Aug 20;373(8):726-36 - PubMed
  13. Nature. 2013 May 2;497(7447):67-73 - PubMed
  14. Cancer Biol Ther. 2015 ;16(12 ):1726-37 - PubMed
  15. Lancet Oncol. 2015 Dec;16(16):e581-2 - PubMed

Publication Types